MNKD earnings

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 29, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) announced today that management will host a conference call to discuss the recent FDA approval of Afrezza® for use in children and adolescents aged 6 and older living with diabetes at 4:30 p.m. Eastern on Friday, May 29, 2026. Presenting from the Company will be its Chief Executive Officer, Michael Castagna, PharmD and Kevin Kaiserman, MD, Senior Vice President, Therapeutic Area Head-Diabetes. Links to the live audio webcast of the presentation will be available on MannKind Corporation's website at: https://investors.mannkindcorp.com/events-and-presentations. Recorded versions

Q1 updates: Q1 2026 total revenues of $90.2M, +15% vs. Q1 2025Built out launch infrastructure and aligned field-based teams for upcoming launchesSettlement of senior convertible notes of $36.3M Program updates: Afrezza® pediatric indication PDUFA date May 29, 2026Furoscix ReadyFlow™ Autoinjector PDUFA date July 26, 2026Nintedanib DPI (MNKD-201) for IPF advancing into Phase 2; INFLO-2 trial anticipates enrolling first patient in Q2 2026Ralinepag DPI (MNKD-1501) announced as collaboration program with United Therapeutics, received additional $5M to support accelerated development Conference call and webcast today at 4:30 p.m. ET DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 06, 2026

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions for cardiometabolic and orphan lung diseases, announced today that it will report its first quarter 2026 financial results on Wednesday, May 6, 2026, after market close. The company will host a webcast beginning at 4:30 p.m. Eastern Time to review the financial results and provide a business update. The webcast will be accessible via a link on MannKind's website at https://investors.mannkindcorp.com/events-and-presentations. A replay will be available in

Q4 2025 revenues of $112M, +46% vs. Q4 2024 Furoscix® Q4 2025 net sales of $23M, +91% vs. Q4 2024 Afrezza® Q4 2025 net sales of $23M, +25% vs. Q4 2024 2025 full year revenues of $349M, +22% vs. 2024Successfully completed the acquisition of scPharmaceuticals Inc. (scPharma)Program updates: Afrezza pediatric indication PDUFA date May 29, 2026Furoscix ReadyFlow™ Autoinjector PDUFA date July 26, 2026  DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions for cardiometabolic and orphan lung diseases, today reporte

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions for cardiometabolic and orphan lung diseases, today announced that it will release its fourth quarter and full year 2025 financial results before the market opens on Thursday, February 26, 2026. MannKind will host a webcast beginning at 9:00 a.m. Eastern Time to review the financial results and provide a business update. The webcast will be accessible via a link on MannKind's website at https://investors.mannkindcorp.com/events-and-presentations. A replay w

MannKind has made the decision to discontinue the ICoN-1 Phase 3 clinical trial evaluating nebulized clofazimine inhalation suspension for nontuberculous mycobacterial (NTM) lung disease, following a futility determination based on medical monitoring dataThis outcome does not impact the development of MNKD-102, MannKind's dry powder inhalation (DPI) formulation of clofazimine, which remains under consideration for future clinical advancementMannKind extends its sincere gratitude to the study participants, investigators, advisors, and clinical site teams for their invaluable contributions to the ICoN-1 studyMannKind will host a conference call today at 9:00 AM EST to discuss this update in mo

Q3 2025 revenues of $82.1M, +17% v. Q3 2024YTD 2025 revenues of $237.0M, +14% v. YTD 2024Completed acquisition of scPharmaceuticals on October 7, accelerating MannKind's revenue growth with FUROSCIX®Program updates: sBLA for Afrezza® in pediatric population accepted for FDA review; PDUFA date of May 29, 2026FUROSCIX ReadyFlow™ Autoinjector sNDA submitted to the FDA MNKD-101 NTM global Phase 3 trial (ICoN-1) achieved interim enrollment target ahead of schedule MNKD-201 IPF Phase 2 trial (INFLO) initiated and expect to enroll first patient in Q1 2026 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today re

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), announced today that its third quarter 2025 financial results will be released before the market opens on November 5, 2025. MannKind will host a webcast beginning at 9 a.m. Eastern Time to discuss the financial results and provide a business update. The webcast will be accessible via a link on MannKind's website at https://investors.mannkindcorp.com/events-and-presentations. A replay will also be available in the same location within 24 hours following the call and be accessible for approximately 90 days. About MannKindMannKind Corporation (NASDAQ:MNKD) is a biopharmaceutica

Acquisition expected to diversify and accelerate double-digit revenue growth with FUROSCIX®, an innovative treatment for edema due to chronic heart failure and chronic kidney disease, addressing significant unmet needUpfront cash payment of $5.35 per share plus one non-tradable contingent value right (CVR) per share payable upon achieving specific regulatory and net sales milestones worth up to $1.00 per CVR in cash Upfront cash payment represents a 36% premium to scPharmaceuticals' 90 trading day VWAP, and total consideration of up to $6.35 per share represents up to a 31% premium to scPharmaceuticals' closing price on August 22, 2025Strengthens organization by integrating scPharmaceuticals

2Q 2025 revenues of $76.5M, +6% v. 2Q 2024YTD 2025 revenues of $154.9M, +12% v. YTD 2024Advanced pipeline: Submitted sBLA for Afrezza® in pediatric populationMNKD-101: NTM global Phase 3 trial (ICoN-1) enrollment ahead of scheduleMNKD-201: Plan to initiate Phase 2 clinical trial for IPF by YE 2025 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today reported financial results for the second quarter 2025 and provided a business update. "The submission of our supplemental Biologics License Application (sBLA) for Afrezza in pediatric patients is a meaningful milestone for MannKind and people living with diabetes," said Mi

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), announced today that its second quarter 2025 financial results will be released before market open on August 6, 2025. MannKind will host a webcast beginning at 9:00 a.m. Eastern Time to discuss the financial results and provide a business update. The webcast will be accessible via a link on MannKind's website at https://investors.mannkindcorp.com/events-and-presentations. A replay will also be available in the same location within 24 hours following the call and be accessible for approximately 90 days. About MannKindMannKind Corporation (NASDAQ:MNKD) focuses on the developme

Conference call to provide corporate updates today at 9:00 am ET 1Q 2025 revenues of $78M, +18% v. 1Q 20241Q 2025 net income of $13M, + 24% v. 1Q 20241Q 2025 non-GAAP net income of $22M, +43% v. 1Q 2024Advanced pipeline: Expect to submit sBLA for Afrezza® in pediatric patients in mid-2025MNKD-101: NTM global Phase 3 trial enrollment on track for interim analysisMNKD-201: Expect to continue to next phase of global development in 2H 2025 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today reported financial results for the first quarter 2025 and provided a business update. "The first quarter was marked by strong y

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 01, 2025 (GLOBE NEWSWIRE) --  MannKind Corporation (NASDAQ:MNKD), announced today that its first quarter 2025 financial results will be released before market open on May 8, 2025. MannKind will host a webcast beginning at 9:00 a.m. Eastern Time to discuss the financial results and provide a business update. Chief Executive Officer Michael Castagna, PharmD, and Chief Financial Officer Chris Prentiss will participate in the conference call from MannKind. The webcast will be accessible via a link on MannKind's website at https://investors.mannkindcorp.com/events-and-presentations. A replay will also be available in the same location within 2

2024 revenues of $286M, +43% v. 2023; 4Q 2024 revenues of $77M, +31% v. 4Q 20232024 net income of $28M; Non-GAAP net income of $68M 4Q 2024 net income of $7M; Non-GAAP net income of $23MReduced debt principal by $236M; remaining convertible debt of $36MYear-end 2024 cash, cash equivalents and investments of $203MAdvanced pipeline: Reported primary endpoint of INHALE-1 for Afrezza in pediatricsProgressed MNKD-101 to Global Phase 3Completed Phase 1 of MNKD-201 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today reported financial results for the quarter and year ended December 31, 2024, and provided a business update. "Th

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), will release its 2024 fourth quarter and full year financial results after market close on Wednesday, February 26, 2025. MannKind will host a webcast beginning at 4:30 p.m. Eastern Time to discuss the financial results and provide a business update. Participating in the conference call from MannKind will be Chief Executive Officer Michael Castagna, PharmD, and Chief Financial Officer Chris Prentiss. The webcast will be accessible via a link on MannKind's website at https://investors.mannkindcorp.com/events-and-presentations. A replay will also be available in the same locatio

Company plans to meet with FDA regarding potential sNDA submission in 1H 2025Call planned today at 8:30 a.m. (ET) to discuss company's diabetes program progression DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, today announced six-month results from its Phase 3 INHALE-1 study of Afrezza (insulin human) Inhalation Powder in children and adolescents (aged 4-17 years of age). MannKind expects to submit a request for a supplemental new drug application (sNDA) meeting with

Conference Call to Begin Today at 4:30 p.m. (ET) 3Q 2024 Total revenues of $70M; +37% vs. 3Q 2023YTD 2024 Total revenues of $209M; +49% vs. YTD 2023YTD 2024 Net income of $20 million; Non-GAAP net income of $45 millionOrphan lung disease studies proceeding as planned MNKD-101 Phase 3 clinical trial expands globallyMNKD-201 Phase 1 successfully completed; Plan to meet with FDA in 1H 2025 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today reported financial results for the quarter ended September 30, 2024. "Our business demonstrated double-digit revenue growth compared to last year, led by Tyvaso DPI revenues,"

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Oct. 31, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), announced today that its third quarter 2024 financial results will be released after market close on Thursday, November 7, 2024. MannKind will host a webcast beginning at 4:30 p.m. Eastern Time to discuss the quarterly results and provide a business update. Participating in the conference call from MannKind will be Chief Executive Officer Michael Castagna, PharmD, and Chief Financial Officer Chris Prentiss. The webcast will be accessible via a link on MannKind's website at https://investors.mannkindcorp.com/events-and-presentations. A replay will also be available in the same

2Q 2024 Total revenues of $72M; +49% vs. 2Q 2023YTD 2024 Total revenues of $139M; +55% vs. YTD 2023YTD 2024 Net income of $9 million; Non-GAAP net income of $29 millionAdvances two orphan lung programs to human studies MNKD-101 Phase 3 clinical trial activities initiatedMNKD-201 Phase 1 clinical trial on schedule to read out 4Q 2024 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Aug. 07, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today reported financial results for the quarter ended June 30, 2024. "We achieved our ninth consecutive quarter of revenue growth and are approaching an annual revenue run rate of over $275 million based on the first half of 2024," said M

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), announced today that it will report its second quarter 2024 financial results before the market opens on Wednesday, August 7, 2024. A press release detailing the quarterly results will be issued the same day approximately one hour prior to the webcast. MannKind will host a webcast beginning at 9:00 a.m. Eastern Time for investors, media, and the general public. Participating in the conference call from MannKind will be Chief Executive Officer Michael Castagna, PharmD, and Chief Financial Officer Chris Prentiss. The webcast will be accessible via a link on MannKind's website a

1Q 2024 Total revenues of $66M; +63% vs. 1Q 20231Q 2024 Net income of $11M; Non-GAAP net income of $15M$304M of cash and cash equivalents and investments at March 31, 2024In early April, repaid Midcap senior-secured debt and Mann Group convertible debt totaling approximately $37M FDA Fast Track designation and IND clearance received for MNKD-101 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today reported financial results for the quarter ended March 31, 2024. "We achieved our eighth consecutive quarter of revenue growth putting us on a run rate of over $250 million in revenue for 2024," said Michael Castagna, PharmD, Chi

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) will release its 2024 first quarter financial results and its management will host a conference call to discuss the financial results and corporate updates at 5:00 PM (Eastern Time) on Wednesday, May 8, 2024. Those interested in listening to the conference call live via the Internet may do so by visiting the Company's website at https://investors.mannkindcorp.com/events-and-presentations under Events & Presentations. About MannKind CorporationMannKind Corporation (NASDAQ:MNKD) focuses on the development and commercialization of innovative therapeutic products and devices to ad

2023 Total revenues of $199M; +99% vs. 20224Q 2023 Total revenues of $58M; +62% vs. 20224Q 2023 Net income of $1M; Non-GAAP net income of $7M$302M of cash and cash equivalents and investments at December 31, 2023 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today reported financial results for the quarter and full year ended December 31, 2023. "We doubled our total revenues to nearly $200 million in 2023 and ended the year with a robust fourth quarter total revenue of $58 million," said Michael Castagna, PharmD, Chief Executive Officer of MannKind Corporation. "With our strong year-end cash position of over

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) will release its 2023 fourth quarter and full year financial results and its management will host a conference call to discuss these results and corporate updates at 5:00 PM (Eastern Time) on Tuesday, February 27, 2024. Presenting from the Company will be its Chief Executive Officer, Michael Castagna, and Chief Financial Officer, Steven Binder. Those interested in listening to the conference call live via the Internet may do so by visiting the Company's website at https://investors.mannkindcorp.com/events-and-presentations under Events & Presentations. About MannKind Corpora

Sagard Healthcare purchased a 1% royalty in Tyvaso DPI® net salesPurchase price of $150 million; additional potential milestone payment of up to $50 million WESTLAKE VILLAGE, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) announced that on December 27, 2023 it sold a 1% royalty in net sales of Tyvaso DPI® (treprostinil) inhalation powder in exchange for up to $200 million, including the purchase price of $150 million and an additional potential milestone payment of up to $50 million. United Therapeutics Corporation licensed Tyvaso DPI from MannKind in 2018 and began marketing it in June 2022 for the treatment of pulmonary arterial hypertension and pulmonary

Conference Call to Begin Today at 5:00 p.m. (ET) 3Q 2023 Total revenues of $51M; +56% vs. 3Q 20223Q YTD 2023 Total revenues of $140M; +121% vs. 3Q YTD 20223Q 2023 Net income of $2M; Non-GAAP net income of $4M3Q 2023 Tyvaso DPI royalties of $20M; +225% vs. 3Q 20223Q 2023 Endocrine BU net revenues of $18M; Afrezza net revenues +24% vs. 3Q 2022 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) --  MannKind Corporation (NASDAQ:MNKD) today reported financial results for the quarter ended September 30, 2023. "We had another strong quarter of revenue growth with total revenues exceeding $51 million," said Michael Castagna, PharmD, Chief Executive Officer of MannKind C

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) will release its 2023 third quarter financial results and year to date financial results and its management will host a conference call to discuss these results and corporate updates at 5:00 PM (Eastern Time) on Tuesday, November 7, 2023. Presenting from the Company will be its Chief Executive Officer, Michael Castagna, and Chief Financial Officer, Steven Binder. Those interested in listening to the conference call live via the Internet may do so by visiting the Company's website at https://investors.mannkindcorp.com/events-and-presentations under Events & Presentatio

Conference Call to Begin Today at 5:00 p.m. (ET) 2Q 2023 Total revenues of $49M; +157% vs. 2Q 2022 2Q 2023 Tyvaso DPI royalties of $19M; +63% vs. 1Q 20232Q 2023 Endocrine Business Unit net revenues of $18M; Afrezza net revenues +27% vs. 2Q 20222Q 2023 Income from operations of $2M; Non-GAAP income from operations of $8M DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Aug. 07, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today reported financial results for the quarter ended June 30, 2023. "We are excited to report positive income from operations in the second quarter driven by growing patient demand for Tyvaso DPI® and Afrezza as well as manufacturing revenues from Tyvaso DP

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., July 31, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) will release its 2023 second quarter financial results and year to date financial results and its management will host a conference call to discuss these results and corporate updates at 5:00 PM (Eastern Time) on Monday, August 7, 2023. Presenting from the Company will be its Chief Executive Officer, Michael Castagna and Chief Financial Officer, Steven Binder. Those interested in listening to the conference call live via the Internet may do so by visiting the Company's website at https://investors.mannkindcorp.com/events-and-presentations under Events & Presentations. About

1Q 2023 Total Revenues of $41 million; +239% vs. 1Q 2022 1Q 2023 Revenues associated with Tyvaso DPI of $23 million 1Q 2023 Loss from operations decreased 72% vs. 1Q 2022 to $6 million $167 million of Cash, Cash Equivalents and Investments at March 31, 2023 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today reported financial results for the quarter ended March 31, 2023. "Demand for Tyvaso DPI® has been very strong, which resulted in $23 million in revenues in the first quarter of 2023," said Michael Castagna, PharmD, Chief Executive Officer of MannKind Corporation. "I'm excited about our inhaled platform and orphan lung

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 02, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) will release its 2023 first quarter financial results and its management will host a conference call to discuss the financial results and corporate updates at 5:00 PM (Eastern Time) on Tuesday, May 9, 2023. Presenting from the Company will be its Chief Executive Officer, Michael Castagna and Chief Financial Officer, Steven Binder. Those interested in listening to the conference call live via the Internet may do so by visiting the Company's website at https://investors.mannkindcorp.com/events-and-presentations under Events & Presentations. About MannKind CorporationMannKind Co

2022 Total Revenues of $100 million; +32% vs. 20212022 Royalties from Tyvaso DPI of $16 million; 4Q 2022 of $9 million4Q 2022 Commercial Products Net Revenue of $17 million;+54% vs. 4Q 2021$173 million of Cash and Cash Equivalents and Investments at December 31, 2022 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 23, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today reported financial results for the fourth quarter and full year ended December 31, 2022. "For 2022, we recognized almost $100 million in total revenues – an incredible triumph for our entire organization," said Michael Castagna, PharmD, Chief Executive Officer of MannKind Corporation. "With our reve

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 16, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) will release its 2022 fourth quarter and full year financial results and its management will host a conference call to discuss these results and corporate updates at 5:00 PM (Eastern Time) on Thursday, February 23, 2023. Presenting from the Company will be its Chief Executive Officer, Michael Castagna and Chief Financial Officer, Steven B. Binder. Those interested in listening to the conference call live via the Internet may do so by visiting the Company's website at mannkindcorp.com under Events & Presentations. A replay will be available on MannKind's website for 14 days.

3Q 2022 Total Revenues of $32.8 million; +48% vs. 3Q 20213Q 2022 Royalties from Tyvaso DPI of $6.2 million3Q 2022 Commercial Products Net Revenue of $16.3 million; +67% vs. 3Q 2021 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today reported financial results for the third quarter and nine months ended September 30, 2022. "In the third quarter, we grew total revenues by 48% over 2021 as our collaboration with United Therapeutics had its first full quarter during which we recognized both manufacturing revenue and royalties associated with the launch of Tyvaso DPI," said Michael Castagna, PharmD, Chief Executive Officer of

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) will release its 2022 third quarter and year to date financial results and its management will host a conference call to discuss these results and corporate updates at 9:00 AM (Eastern Time) on Tuesday, November 8, 2022. Presenting from the Company will be its Chief Executive Officer, Michael Castagna and Chief Financial Officer, Steven Binder. Those interested in listening to the conference call live via the Internet may do so by visiting the Company's website at https://mannkindcorp.com/news-events/ under Events & Presentations. About MannKindMannKind Corporation (NASDAQ:M

Conference Call to Begin Today at 5:00 p.m. (ET) Tyvaso DPI™ approved by the FDA in May representing the second FDA-approved product using the Technosphere® inhalation platform V-Go® acquired May 31; $2.1 million Net Revenue recognized for June2Q 2022 Commercial Products Net Revenue of $12.7 million; +28% vs. 2Q 20212Q 2022 Collaboration and Services Revenue of $5.9 million; +171% vs. 1Q 2022 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today reported financial results for the second quarter and first half of 2022. "In the second quarter, we achieved multiple milestones that position the Company for growth over the ne

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) will release its 2022 second quarter and year to date financial results and its management will host a conference call to discuss these results and corporate updates at 5:00 PM (Eastern Time) on Tuesday, August 9, 2022. Presenting from the Company will be its Chief Executive Officer, Michael Castagna and Chief Financial Officer, Steven Binder. Those interested in listening to the conference call live via the Internet may do so by visiting the Company's website at https://mannkindcorp.com/news-events/ under Events. About MannKind CorporationMannKind Corporation (NASDAQ:MNKD)

1Q 2022 Afrezza Net Revenue of $9.8 million; +21% vs. 1Q 20211Q 2022 Afrezza Gross Margin 77%; Gross Profit +99% vs 1Q 2021$233.0 million of Cash, Cash Equivalents, and Investments at March 31, 2022Tyvaso DPI PDUFA date May 2022 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today reported financial results for the quarter ended March 31, 2022. "As we approach the FDA action date for Tyvaso DPI, our company is focused on supporting United Therapeutics in their planned commercial launch," said Michael Castagna, PharmD, Chief Executive Officer of MannKind Corporation. "Our endocrine business unit execution has resulted in Af

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) will release its 2022 first quarter financial results and its management will host a conference call to discuss the financial results and corporate updates at 5:00 PM (Eastern Time) on Thursday, May 5, 2022. Presenting from the Company will be its Chief Executive Officer, Michael Castagna and Chief Financial Officer, Steven Binder. Those interested in listening to the conference call live via the Internet may do so by visiting the Company's website at https://mannkindcorp.com/news-events/ under Events. About MannKind CorporationMannKind Corporation (NASDAQ:MNKD) focuses on

Conference Call to Begin Today at 5:00 p.m. (ET) 2021 Total Revenues of $75.4 million; +16% vs. 2020 4Q 2021 Afrezza Net Revenue of $11.3 million; +13% vs. 4Q 2020$260.7 million of Cash, Cash Equivalents and Investments at December 31, 2021Commenced clofazimine Phase 1 clinical trial in 1Q 2022Tyvaso DPI review deadline extended to May 2022 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today reported financial results for the fourth quarter and full year ended December 31, 2021. "We had a solid fourth quarter with Afrezza net revenue hitting a record $11.3 million and we ended the year with over $260 million in cash an

WESTLAKE VILLAGE, Calif. and DANBURY, Conn., Feb. 24, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, was informed that the U.S. Food and Drug Administration (FDA) issued an information request to United Therapeutics Corporation earlier this month regarding the New Drug Application (NDA) for Tyvaso DPI, requesting additional information regarding the pulmonary safety of Tyvaso DPI related to a pending Citizen Petition. United Therapeutics promptly responded to the agency's request. MannKind has now learned that the FDA considers the r

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 21, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) will release its 2021 fourth quarter and full year financial results, and its management will host a conference call to discuss the financial results and corporate updates at 5:00 p.m. (Eastern Time) on Thursday, February 24, 2022. Presenting from the Company will be its Chief Executive Officer Michael Castagna and Chief Financial Officer Steven Binder. Those interested in listening to the conference call live via the internet may do so by visiting the Investors page of the Company's website at mannkindcorp.com under Events & Presentations. About MannKind CorporationMannKind

RADNOR, Pa., Nov. 16, 2021 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals (NASDAQ:NRXP) (NRx), a clinical-stage, biopharmaceutical company, today provided a business update and financial results for the quarter ended September 30, 2021. NRx will host a conference call Tuesday morning, November 16th, at 8:30 AM Eastern Time to discuss its business update and third-quarter financial results. Investors and the general public are invited to listen to a live audio webcast of the conference call, which may be accessed five minutes before the start of the call by dialing (877) 705-6003 (U.S.), (201) 493-6725 (International) Conference ID: 13724953, or through the webcast link NRx Pharmaceuticals Third

Conference Call to Begin Today at 5:00 p.m. (ET) 3Q 2021 Total Revenues of $22.2 million; +45% vs. 3Q 20203Q 2021 Afrezza Net Revenue of $9.8 million; +34% vs. 3Q 2020$181.1 million of Cash, Cash Equivalents and Investments at September 30, 2021Sale-Leaseback of Danbury manufacturing facility closed November 8, 2021 WESTLAKE VILLAGE, Calif., Nov. 09, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today reported financial results for the quarter and nine months ended September 30, 2021. "The MannKind team continues to stay focused and execute our corporate objectives of preparing for the commercial launch of Tyvaso DPI, moving our pipeline forward and growing Afrezza," said

WESTLAKE VILLAGE, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) will release its 2021 third quarter financial results and its management will host a conference call to discuss the financial results and corporate updates at 5:00 PM (Eastern Time) on Tuesday, November 9, 2021. Presenting from the Company will be its Chief Executive Officer, Michael Castagna and Chief Financial Officer, Steven B. Binder. Those interested in listening to the conference call live via the Internet may do so by visiting the Company's website at Events & Presentations https://investors.mannkindcorp.com/events-and-presentations.  A replay will also be available on MannKind's website

Conference Call to Begin Today at 5:00 PM ET 2Q 2021 Total Revenues of $23.3 million; +54% vs. 2Q 20202Q 2021 Afrezza Net Revenue of $10.0 million; +43% vs. 2Q 2020$201.4 million of Cash, Cash Equivalents and Investments at June 30, 2021 WESTLAKE VILLAGE, Calif., Aug. 11, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today reported financial results for the quarter and six months ended June 30, 2021. "I am really proud of how our team has executed so far in 2021 supporting the growth of Afrezza and preparing for the potential commercial launch of Tyvaso DPI," said Michael Castagna, Chief Executive Officer of MannKind Corporation. "With the issuance of the convertible debt

WESTLAKE VILLAGE, Calif., Aug. 04, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) will release its 2021 second quarter financial results and its management will host a conference call to discuss the financial results and corporate updates at 5:00 PM (Eastern Time) on Wednesday, August 11, 2021. Presenting from the Company will be its Chief Executive Officer, Michael Castagna and Chief Financial Officer, Steven B. Binder. Those interested in listening to the conference call live via the Internet may do so by visiting the Company's website at https://investors.mannkindcorp.com/events-and-presentations Events & Presentations.  A replay will also be available on MannKind's websi